MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm13133784

Медицинская библиотека · Journal of clinical medicine · 2024

Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m2) with Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis.

Karakasis Paschalis, Ktenopoulos Nikolaos, Pamporis Konstantinos, Sagris Marios, Soulaidopoulos Stergios, Gerogianni Maria, Leontsinis Ioannis, Giannakoulas George, Tousoulis Dimitris, Fragakis Nikolaos, Tsioufis Konstantinos

СтатьяОбзорПеревод в очереди

Аннотация

Background

Real-world data show limited utilization of direct oral anticoagulants (DOACs) in obese patients (body mass index [BMI] ≥ 30 kg/m2) due to concerns regarding their efficacy and safety in this demographic. Aim: This review aimed to consolidate current evidence on the efficacy and safety of DOACs versus warfarin in obese patients with non-valvular atrial fibrillation (AF) or venous thromboembolism (VTE). The primary efficacy outcome assessed a composite of all-cause mortality, stroke, systemic embolism (SE), and myocardial infarction (MI).

Methods

A systematic search was conducted in MEDLINE, SCOPUS, and Cochrane databases from inception to December 28, 2023. Data were synthesized using random-effects meta-analysis.

Results

A total of 35 studies involving 434,320 participants were analyzed. DOAC use was associated with a significant reduction in the risk of the composite outcome (RR = 0.80, 95% CI [0.65, 0.98], I2 = 95%), hemorrhagic stroke (RR = 0.58, 95% CI [0.38, 0.88], I2 = 92%), major bleeding (RR = 0.76, 95% CI [0.63, 0.92], I2 = 94%), gastrointestinal bleeding (RR = 0.59, 95% CI [0.49, 0.72], I2 = 88%), and intracranial bleeding (RR = 0.45, 95% CI [0.34, 0.60], I2 = 44%) compared to warfarin. A non-significant benefit of DOACs was observed for all-cause mortality, MI, the composite of stroke or SE, ischemic stroke, SE, VTE, and minor bleeding compared to warfarin. Subgroup analysis indicated no significant effect modification based on the indication for anticoagulation or study design.

Conclusions

DOACs demonstrated a favorable efficacy and safety profile in obese individuals compared to warfarin.

Для цитирования: Karakasis Paschalis, Ktenopoulos Nikolaos, Pamporis Konstantinos, Sagris Marios, Soulaidopoulos Stergios, Gerogianni Maria, Leontsinis Ioannis, Giannakoulas George, Tousoulis Dimitris, Fragakis Nikolaos, Tsioufis Konstantinos. Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m2) with Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis.. Journal of clinical medicine. 2024. DOI: 10.3390/jcm13133784.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.